friday, September 20, 2024
| Agenda | |
|---|---|
| Session 1: Cellular Therapy in Solid Tumors | |
| Unmasking Hidden Targets for Adoptive T-cell Immunotherapy of Ovarian Cancer Kunle Odunsi, MD, PhD University of Chicago | |
| IL13RA2-directed CAR T-cells for Pediatric Brain Tumors Leo Wang, MD, PhD City of Hope National Medical Center | |
| Janet Rowley Keynote Lecture | |
| Avoiding Alloreactive T-cells to Enable Off the Shelf Therapy for Lymphoma Cliona M. Rooney, PhD Baylor College of Medicine | |
| Session 2: Overcoming Resistance and Relapse to Cellular Therapy | |
| Genetic and Pharmacologic Interventions to Improve CAR T-cell Persistence and Function in Pre-clinical Lymphoma Models Justin Kline, MD University of Chicago | |
| Curing Cancer with CAR T-cells: It’s a Team Effort Joseph Melenhorst, PhD Cleveland Clinic | |
| Jonas Memorial Keynote Lecture | |
| Molecular Cell Shielding – A Therapeutic Platform Approach for Hematologic Diseases Lukas Jeker, MD, PhD Basel University Hospital and University of Basel | |
| Session 3: Advances in Cellular Therapy Engineering | |
| In Vivo CAR T-cell Generation in Non-human Primates and Tumor-bearing Humanized Mice Using Lentiviral Particles Displaying a Multi-domain Fusion Protein Byoung Ryu, PhD Umoja Biopharma | |
| Using Lipid Nanoparticles to Produce mRNA CAR T Cell Immunotherapies Ann Metzloff, BSE University of Pennsylvania | |
| Session 4: Novel Cellular Therapies – From Bench to Bedside | |
| Advancing Bispecific LV20.19 CAR T-cells at the Medical College of Wisconsin Nirav Shah, MD, MSHP Medical College of Wisconsin | |
| CAR T-cell Therapy for T-cell Malignancies Armin Ghobadi, MD Washington University in St. Louis | |
| Advancing Cell-Based Cancer Immunotherapy Through Stem Cell Engineering Lili Yang, PhD University of California, Los Angeles |